| Not Yet Recruiting | Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital NCT07505420 | Assiut University | — |
| Not Yet Recruiting | Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants NCT07417657 | Phuc Huu Phan | — |
| Recruiting | A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Childre NCT07402512 | Simcere Pharmaceutical Co., Ltd | Phase 3 |
| Not Yet Recruiting | RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV NCT07346963 | Eskisehir Osmangazi University | — |
| Recruiting | Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals NCT06817889 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) NCT07239583 | Tam Anh Research Institute | — |
| Active Not Recruiting | SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER NCT06546800 | Pfizer | — |
| Active Not Recruiting | Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years NCT06904222 | Guangzhou Patronus Biotech Co., Ltd. | Phase 1 |
| Active Not Recruiting | The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, o NCT06551506 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Active Not Recruiting | Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in A NCT06604767 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older NCT06251024 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV NCT06206720 | Vigonvita Life Sciences | Phase 2 |
| Completed | Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory S NCT06237296 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Terminated | A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infecti NCT06079320 | Pfizer | Phase 2 / Phase 3 |
| Completed | A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Heal NCT05987072 | Pfizer | Phase 1 |
| Completed | Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate NCT06134648 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and NCT05687279 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) NCT04767373 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers NCT04491877 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants NCT06424795 | University of Rochester | — |
| Completed | A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vac NCT03473002 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the NCT02254421 | Gilead Sciences | Phase 2 |
| Completed | A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Re NCT02309320 | Ablynx, a Sanofi company | Phase 1 / Phase 2 |
| Completed | Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus ( NCT02135614 | Gilead Sciences | Phase 2 |
| Completed | Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children Wi NCT02016690 | AbbVie | — |
| Completed | ALX-0171 Safety Study in Adults With Hyperresponsive Airways NCT01909843 | Ablynx, a Sanofi company | Phase 1 |
| Completed | Surveillance of Synagis in Korean Pediatric Patients NCT01537198 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less NCT01466062 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin Am NCT01297504 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children NCT01006629 | Abbott | Phase 2 / Phase 3 |
| Completed | Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respirato NCT01107535 | Abbott | — |
| Completed | Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children NCT00593918 | University of Wisconsin, Madison | — |
| Completed | Prevention of RSV Infections in Bone Marrow Transplant Recipients NCT00001903 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |